+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ximelagatran, an oral direct thrombin inhibitor, has no effect on the pharmacokinetics of P450-metabolized drugs



Ximelagatran, an oral direct thrombin inhibitor, has no effect on the pharmacokinetics of P450-metabolized drugs



Clinical Pharmacology and Therapeutics 71(2): P65




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 036058177

Download citation: RISBibTeXText


Related references

The effect of the oral direct thrombin inhibitor ximelagatran on the pharmacokinetics of P450-metabolized drugs, in healthy male volunteers. Blood 98(11 Part 2): 89b, 2001

Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran. Clinical Pharmacology and Therapeutics 75(2): P78, 2004

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical Pharmacokinetics 42(4): 381-392, 2003

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. Clinical Pharmacokinetics 45(1): 77-84, 2006

Mild-to-moderate liver impairment has no influence on the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor. Clinical Pharmacology and Therapeutics 71(2): P99, 2002

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. European Journal of Clinical Pharmacology 59(1): 35-43, 2003

The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. Journal of Clinical Pharmacology 44(4): 388-393, 2004

No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clinical Pharmacokinetics 42(5): 475-484, 2003

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers. European Journal of Clinical Pharmacology 63(6): 571-581, 2007

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical Pharmacokinetics 42(8): 755-764, 2003

No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clinical Pharmacokinetics 42(5): 485-492, 2003

Pharmacokinetics of melagatran after oral dosing with ximelagatran, a direct thrombin inhibitor, in patients with acute venous thromboembolism. Clinical Pharmacology and Therapeutics 71(2): P61, 2002

The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: A mini-review. Thrombosis Research 109(Suppl 1): S9-S15, 2003

Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation receiving long-term treatment A population analysis by nonlinear mixed effect modeling. Clinical Pharmacology and Therapeutics 71(2): P31, 2002